REGN vs BIIB Stock Comparison: AI Score, Valuation, Performance and Upside
Regeneron and Biogen are both innovative biopharma companies with flagship products, but their risk profiles are sharply different. REGN's Dupixent is a proven, rapidly growing blockbuster with multiple expanding indications providing near-term earnings visibility. BIIB's Leqembi is a pioneering Alzheimer's drug but faces significant commercial challenges that have made its ramp much slower than anticipated.
Investors must choose between Regeneron's high-quality, high-multiple growth driven by Dupixent's proven commercial success versus Biogen's lower-multiple value proposition dependent on Leqembi proving it can overcome commercialization barriers at scale.
REGN holds the edge across 3 of 5 key metrics in this comparison. BIIB has delivered stronger 1-year price return (+49.85% vs +31.09%), though REGN has the better forward P/E setup (13.10x vs 13.21x for BIIB). REGN leads on both revenue growth (16.70%) and operating margin (33.11%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +5.82% for REGN and +8.11% for BIIB.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want high-quality biopharma growth anchored by Dupixent's expanding multi-indication platform
- value proprietary antibody discovery technology providing durable pipeline optionality
- prefer companies with strong balance sheets and consistent earnings growth
- are comfortable with premium valuation for superior pipeline visibility
- believe Leqembi's Alzheimer's market will overcome payer and access barriers over time
- see deep-value potential in a neuroscience leader trading at a discount to intrinsic value
- want exposure to a potential breakthrough Alzheimer's franchise at an early commercial stage
- are comfortable with higher uncertainty and longer timelines for the thesis to play out
| Metric | REGN | BIIB |
|---|---|---|
| AI scorei | 43.7 | 29.0 |
| AI ranki | #860 | #2343 |
| Latest closei | $784.85 | $215.50 |
| 1M returni | -6.66% | -2.74% |
| 6M returni | +6.43% | +17.50% |
| 1Y returni | +31.09% | +49.85% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | REGN | BIIB |
|---|---|---|
| 1Y ago | $13.11K (+31.1%) started 2025-09-18 | $14.99K (+49.9%) started 2025-09-18 |
| 5Y ago | $12.3K (+23.0%) started 2021-09-20 | $7.22K (-27.8%) started 2021-09-20 |
| 10Y ago | $19.56K (+95.6%) started 2016-09-19 | $7.1K (-29.0%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | REGN | BIIB |
|---|---|---|
| Market capi | $81.77B | $32.28B |
| Trailing P/Ei | 19.65 | 38.74 |
| Forward P/Ei | 13.10 | 13.21 |
| Price/Salesi | 3.78 | 1.99 |
| EV/Revenuei | 4.76 | 3.92 |
| Analyst targeti | $840.43 | $236.22 |
| Target upsidei | +5.82% | +8.11% |
| Metric | REGN | BIIB |
|---|---|---|
| Revenue growthi | 16.70% | 3.40% |
| Earnings growthi | -4.50% | -84.80% |
| EPS growthi | -4.50% | -84.80% |
| FCF margini | +19.73% | +12.63% |
| Operating margini | 33.11% | 25.06% |
| Profit margini | 27.87% | 8.32% |
| ROIC proxyi | 14.04% | 4.58% |
| Return on equityi | 14.04% | 4.58% |
| Dividend yieldi | 0.47% | N/A |
| Payout ratioi | 9.01% | 0.00% |
| Dividend growth streaki | No increase yet | N/A |
| Betai | 0.19 | 0.16 |
| Debt/equityi | 8.54 | 44.33 |
| Current ratioi | 3.33 | 1.86 |
| Quick ratioi | 2.63 | 0.94 |
Over the past year, REGN and BIIB have moved weakly in the same direction (correlation of 0.36), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | REGN | BIIB |
|---|---|---|---|
| 1Y | Growthi | +31.09% | +49.85% |
| CAGRi | +31.11% | +49.89% | |
| Volatilityi | 33.54% | 35.01% | |
| Sharpe ratioi | 0.84 | 1.21 | |
| Sortino ratioi | 1.31 | 1.91 | |
| Max drawdowni | 26.05% | 14.34% | |
| Current drawdowni | 7.88% | 4.01% | |
| Avg drawdowni | 8.23% | 4.87% | |
| Ulcer Indexi | 11.06% | 5.87% | |
| Max daily dropi | 9.82% | 8.17% | |
| Max wkly dropi | 12.87% | 12.37% | |
| 5Y | Growthi | +22.80% | -27.80% |
| CAGRi | +4.20% | -6.31% | |
| Volatilityi | 31.12% | 34.65% | |
| Sharpe ratioi | 0.14 | -0.16 | |
| Sortino ratioi | 0.20 | -0.25 | |
| Max drawdowni | 59.69% | 64.35% | |
| Current drawdowni | 34.51% | 32.25% | |
| Avg drawdowni | 20.20% | 31.70% | |
| Ulcer Indexi | 27.95% | 35.89% | |
| Max daily dropi | 19.01% | 8.17% | |
| Max wkly dropi | 20.21% | 13.62% | |
| 10Y | Growthi | +95.37% | -29.00% |
| CAGRi | +6.93% | -3.37% | |
| Volatilityi | 32.13% | 41.37% | |
| Sharpe ratioi | 0.23 | 0.01 | |
| Sortino ratioi | 0.34 | 0.01 | |
| Max drawdowni | 59.69% | 72.66% | |
| Current drawdowni | 34.51% | 48.04% | |
| Avg drawdowni | 21.33% | 34.71% | |
| Ulcer Indexi | 26.89% | 39.18% | |
| Max daily dropi | 19.01% | 29.23% | |
| Max wkly dropi | 20.21% | 34.30% |
| Category | REGN | BIIB |
|---|---|---|
| Company | Regeneron Pharmaceuticals, Inc. | Biogen Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Core business | Regeneron is a science-driven biopharmaceutical company with a technology platform (Veloci-Suite) that enables rapid antibody discovery. Its commercial portfolio is anchored by Dupixent (dupilumab) for atopic dermatitis and other Th2-driven inflammatory diseases, growing at 25%+ annually with multiple ongoing label expansions. Eylea (aflibercept) for eye diseases provides a second major revenue stream, though facing biosimilar competition from Eylea HD (its own successor product). REGN-EB3 for Ebola and odronextamab in lymphoma represent additional pipeline assets. | Biogen pioneered the treatment of multiple sclerosis and remains a leader in MS with drugs including Tecfidera (now generic), Tysabri, and Vumerity. Its Alzheimer's franchise — lecanemab (Leqembi, developed with Eisai) — represents the company's highest-stakes pipeline bet, as one of the first amyloid-clearing drugs to show clinical benefit. Biogen also has biosimilars revenue and a neuroscience portfolio including Skyclarys for Friedreich's ataxia. |
| Investor focus | Investors focus on Dupixent's expanding indications (COPD, prurigo nodularis, and others), the Eylea to Eylea HD transition success, and the depth of the broader pipeline beyond these two anchors. | Investors track Leqembi's commercial uptake (slowed by payer coverage and infusion logistics challenges), MS product revenue retention against generic competition, and whether the broader neuroscience pipeline can provide a sustainable revenue growth bridge. |
- Dupixent is one of the fastest-growing large-molecule drugs globally with 10+ approved indications
- Veloci-Suite antibody discovery platform provides ongoing pipeline generation advantage
- Strong balance sheet with significant cash enabling pipeline investment and buybacks
- Leqembi (lecanemab) is one of the first approved Alzheimer's disease-modifying treatments
- Deep neuroscience expertise and relationships spanning 40+ years of MS drug development
- Eisai partnership on Leqembi shares development costs and commercialization risk
- Eylea biosimilar competition creating headwinds for the legacy eye care franchise
- Dupixent growth will eventually slow as market penetration matures in lead indications
- High dependence on two products (Dupixent and Eylea) for the majority of revenue
- Leqembi commercial uptake materially below initial projections due to payer and logistical hurdles
- MS revenue base eroding from generic Tecfidera competition
- Alzheimer's drug market may take years to scale, creating a prolonged revenue gap
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.